Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1970 Dec;40(4):747–758. doi: 10.1111/j.1476-5381.1970.tb10652.x

The effect of thyroid hormones on the action of some centrally acting drugs

P F Coville, J M Telford
PMCID: PMC1702903  PMID: 5531341

Abstract

1. The effect of administration of thyroxine or thyroidectomy on the pharmacological action of (+)-amphetamine, caffeine, hexobarbitone and morphine was determined in rats or mice.

2. Locomotor activity induced by (+)-amphetamine or caffeine was increased by hyperthyroidism and decreased by hypothyroidism.

3. The LD50s of (+)-amphetamine and caffeine in hyperthyroid rats were 1/30 and 2/5 that of control rats. With each drug, the LD50 regression lines in hyperthyroid and control rats were not parallel, suggesting that hyperthyroidism modifies the mechanism of the toxic effects. Hypothyroidism reduced toxicity to (+)-amphetamine.

4. Hexobarbitone sleeping time was prolonged in hyperthyroid male rats, but was shortened in hyperthyroid female rats. In control rats, sleeping time was approximately four times as long in females as it was in males. Ethinyloestradiol treatment and castration also prolonged sleeping time in male rats. No further prolongation was produced by combined administration of thyroxine and ethinyloestradiol, but thyroxine further prolonged the sleeping time of castrated rats indicating that its mode of action in producing these changes is not mediated via sex hormones.

5. In contrast to rats, a sex difference in the duration of action of hexobarbitone was not found in mice. Thyroxine prolonged sleeping time equally in each sex.

6. Analgesia induced by morphine in mice was unaffected by hyperthyroidism. No increase in sedative or `Straub tail' activity could be detected, but toxicity was increased when higher doses of morphine were used.

7. The mechanism by which thyroid hormones produce these changes in sensitivity to centrally acting drugs is discussed. It is suggested that the effects of thyroxine vary according to whether the mode of action of the drug or its metabolism is modified.

Full text

PDF
747

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BURN J. H., RAND M. J. The action of sympathomimetic amines in animals treated with reserpine. J Physiol. 1958 Dec 4;144(2):314–336. doi: 10.1113/jphysiol.1958.sp006104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. BUTCHER R. W., SUTHERLAND E. W. Adenosine 3',5'-phosphate in biological materials. I. Purification and properties of cyclic 3',5'-nucleotide phosphodiesterase and use of this enzyme to characterize adenosine 3',5'-phosphate in human urine. J Biol Chem. 1962 Apr;237:1244–1250. [PubMed] [Google Scholar]
  3. Bartelstone H. J., Nasmyth P. A., Telford J. M. The significance of adenosine cyclic 3',5'-monophosphate for the contraction of smooth muscle. J Physiol. 1967 Jan;188(2):159–176. doi: 10.1113/jphysiol.1967.sp008131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Brodie B. B., Davies J. I., Hynie S., Krishna G., Weiss B. Interrelationships of catecholamines with other endocrine systems. Pharmacol Rev. 1966 Mar;18(1):273–289. [PubMed] [Google Scholar]
  5. CARRIER R. N., BUDAY P. V. Augmentation of toxicity of monoamine oxidase inhibitor by thyroid feeding. Nature. 1961 Sep 9;191:1107–1107. doi: 10.1038/1911107a0. [DOI] [PubMed] [Google Scholar]
  6. COCHIN J., SOKOLOFF L. Effects of administration of L-thyroxin on liver N-demethylating activity in normal and morphine-treated rats. Proc Soc Exp Biol Med. 1960 Jul;104:504–506. doi: 10.3181/00379727-104-25890. [DOI] [PubMed] [Google Scholar]
  7. CONNEY A. H., GARREN L. Contrasting effects of thyroxin on zoxazolamine and hexobarbital metabolism. Biochem Pharmacol. 1961 Jun;6:257–262. doi: 10.1016/0006-2952(61)90139-3. [DOI] [PubMed] [Google Scholar]
  8. Coville P. F., Telford J. M. Changes in drug sensitivity in hyperthyroidism. Br J Pharmacol. 1969 May;36(1):189P–190P. [PMC free article] [PubMed] [Google Scholar]
  9. Coville P. F., Telford J. M. Influence of thyroid hormones on the sensitivity of cardiac and smooth muscle to biogenic amines and other drugs. Br J Pharmacol. 1970 May;39(1):49–68. doi: 10.1111/j.1476-5381.1970.tb09555.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Dolfini E., Ramirez del Angel A., Garattini S., Valzelli L. Brain catecholamine release by dexamphetamine in three strains of mice. Eur J Pharmacol. 1970 Mar;9(3):333–336. doi: 10.1016/0014-2999(70)90231-1. [DOI] [PubMed] [Google Scholar]
  11. HALPERN B. N., DRUDI-BARACCO C., BESSIRARD D. EXALTATION OF TOXICITY OF SYMPATHOMIMETIC AMINES BY THYROXINE. Nature. 1964 Oct 24;204:387–388. doi: 10.1038/204387a0. [DOI] [PubMed] [Google Scholar]
  12. Kato R., Takanaka A., Takahashi A., Onoda K. Species differences in the alteration of drug-metabolizing activities of liver microsomes by thyroxine treatment. Jpn J Pharmacol. 1969 Mar;19(1):5–18. doi: 10.1254/jjp.19.5. [DOI] [PubMed] [Google Scholar]
  13. MOORE K. E. TOXICITY AND CATECHOLAMINE RELEASING ACTIONS OF D- AND L-AMPHETAMINE IN ISOLATED AND AGGREGATED MICE. J Pharmacol Exp Ther. 1963 Oct;142:6–12. [PubMed] [Google Scholar]
  14. MURAD F., CHI Y. M., RALL T. W., SUTHERLAND E. W. Adenyl cyclase. III. The effect of catecholamines and choline esters on the formation of adenosine 3',5'-phosphate by preparations from cardiac muscle and liver. J Biol Chem. 1962 Apr;237:1233–1238. [PubMed] [Google Scholar]
  15. Moore K. E. Amphetamine toxicity in hyperthyroid mice: effects on endogenous catecholamines. Biochem Pharmacol. 1965 Dec;14(12):1831–1837. doi: 10.1016/0006-2952(65)90273-x. [DOI] [PubMed] [Google Scholar]
  16. PRANGE A. J., Jr, LIPTON M. A. Enhancement of imipramine mortality in hyperthyroid mice. Nature. 1962 Nov 10;196:588–589. doi: 10.1038/196588a0. [DOI] [PubMed] [Google Scholar]
  17. Skobba T., Miya T. S. Hyperthermic responses and toxicity of chlorpromazine in L-thyroxine sodium-treated rats. Toxicol Appl Pharmacol. 1969 Jan;14(1):176–181. doi: 10.1016/0041-008x(69)90177-x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES